159 related articles for article (PubMed ID: 14634493)
1. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
Johnson BA; Ait-Daoud N; Ma JZ; Wang Y
Alcohol Clin Exp Res; 2003 Nov; 27(11):1773-9. PubMed ID: 14634493
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron reduces the craving of biologically predisposed alcoholics.
Johnson BA; Roache JD; Ait-Daoud N; Zanca NA; Velazquez M
Psychopharmacology (Berl); 2002 Apr; 160(4):408-13. PubMed ID: 11919668
[TBL] [Abstract][Full Text] [Related]
3. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Johnson BA; Ait-Daoud N; Prihoda TJ
Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
[TBL] [Abstract][Full Text] [Related]
4. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.
Kranzler HR; Pierucci-Lagha A; Feinn R; Hernandez-Avila C
Alcohol Clin Exp Res; 2003 Jul; 27(7):1150-5. PubMed ID: 12878921
[TBL] [Abstract][Full Text] [Related]
5. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Ait-Daoud N; Johnson BA; Javors M; Roache JD; Zanca NA
Alcohol Clin Exp Res; 2001 Jun; 25(6):847-9. PubMed ID: 11410720
[TBL] [Abstract][Full Text] [Related]
6. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
[TBL] [Abstract][Full Text] [Related]
7. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
Roache JD; Wang Y; Ait-Daoud N; Johnson BA
Alcohol Clin Exp Res; 2008 Aug; 32(8):1502-12. PubMed ID: 18565156
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
[TBL] [Abstract][Full Text] [Related]
10. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.
Johnson BA; Roache JD; Ait-Daoud N; Javors MA; Harrison JM; Elkashef A; Mojsiak J; Li SH; Bloch DA
Drug Alcohol Depend; 2006 Oct; 84(3):256-63. PubMed ID: 16631323
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism".
Krystal JH; Gueorguieva R; Cramer J; Collins J; Rosenheck R;
Alcohol Clin Exp Res; 2008 Jan; 32(1):85-91. PubMed ID: 18070245
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron alters human alcohol intoxication.
Swift RM; Davidson D; Whelihan W; Kuznetsov O
Biol Psychiatry; 1996 Sep; 40(6):514-21. PubMed ID: 8879472
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
14. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Dawes MA; Johnson BA; Ait-Daoud N; Ma JZ; Cornelius JR
Addict Behav; 2005 Jul; 30(6):1077-85. PubMed ID: 15925118
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R
Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042
[TBL] [Abstract][Full Text] [Related]
16. 24 hours on-call and acute fatigue no longer worsen resident mood under the 80-hour work week regulations.
Kiernan M; Civetta J; Bartus C; Walsh S
Curr Surg; 2006; 63(3):237-41. PubMed ID: 16757379
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil.
Corrêa Filho JM; Baltieri DA
Addict Behav; 2013 Apr; 38(4):2044-51. PubMed ID: 23396176
[TBL] [Abstract][Full Text] [Related]
18. Evaluating readiness and treatment seeking effects in a pharmacotherapy trial for alcohol dependence.
Penberthy JK; Ait-Daoud N; Breton M; Kovatchev B; DiClemente CC; Johnson BA
Alcohol Clin Exp Res; 2007 Sep; 31(9):1538-44. PubMed ID: 17624996
[TBL] [Abstract][Full Text] [Related]
19. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
20. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
Theal JJ; Toosi MN; Girlan L; Heslegrave RJ; Huet PM; Burak KW; Swain M; Tomlinson GA; Heathcote EJ
Hepatology; 2005 Jun; 41(6):1305-12. PubMed ID: 15915460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
